



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

May 30, 2019

Neil Kumar, Ph.D.  
Chief Executive Officer  
BridgeBio Pharma, Inc.  
421 Kipling Street  
Palo Alto, CA 94301

**Re: BridgeBio Pharma, Inc.**  
**Registration Statement on Form S-1**  
**Exhibit Nos. 10.9, 10.10, 10.11, 10.12, 10.13, 10.14, 10.15, 10.16 and 10.17**  
**Filed May 24, 2019**  
**File No. 333-231759**

Dear Dr. Kumar:

We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance